Pharming Group N.V. Files Form 6-K

Ticker: PHAR · Form: 6-K · Filed: 2024-10-24T00:00:00.000Z

Sentiment: neutral

Topics: filing, press-release

TL;DR

Pharming Group N.V. filed a 6-K with an attached press release on Oct 24, 2024. Details inside.

AI Summary

Pharming Group N.V. filed a Form 6-K on October 24, 2024, to furnish a press release dated October 24, 2024. The filing itself does not contain specific financial figures or operational updates beyond referencing the attached press release.

Why It Matters

This filing indicates that Pharming Group N.V. is providing an update to the SEC, likely containing important information for investors that was released to the public.

Risk Assessment

Risk Level: low — This is a routine filing to furnish a press release, not containing new material financial information within the 6-K itself.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing?

The Form 6-K is being filed to furnish a press release of Pharming Group N.V., dated October 24, 2024, as Exhibit 99.1.

What is the exact filing date of this Form 6-K?

The Form 6-K was filed on October 24, 2024.

What is the principal executive office address of Pharming Group N.V. as listed in the filing?

The address is Darwinweg 24, 2333 CR Leiden, The Netherlands.

Does Pharming Group N.V. file annual reports under Form 20-F or Form 40-F?

Pharming Group N.V. indicates it files annual reports under Form 20-F.

What is the Commission File Number for Pharming Group N.V.?

The Commission File Number is 001-39822.

From the Filing

0001828316-24-000035.txt : 20241024 0001828316-24-000035.hdr.sgml : 20241024 20241024060228 ACCESSION NUMBER: 0001828316-24-000035 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20241024 FILED AS OF DATE: 20241024 DATE AS OF CHANGE: 20241024 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharming Group N.V. CENTRAL INDEX KEY: 0001828316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39822 FILM NUMBER: 241390462 BUSINESS ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR BUSINESS PHONE: 31 (0)71 5247 400 MAIL ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR FORMER COMPANY: FORMER CONFORMED NAME: Pharming Group Group N.V. DATE OF NAME CHANGE: 20201014 6-K 1 a2024q3pressrelease.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-39822 Pharming Group N.V. (Exact Name of Registrant as Specified in Its Charter) Darwinweg 24 2333 CR Leiden The Netherlands (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., dated October 24, 2024. 1 EXHIBIT INDEX Exhibit No. Description 99.1 Pharming Group reports third quarter 2024 financial results and provides business update SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Pharming Group N.V. By: /s/ Sijmen de Vries Name: Sijmen de Vries Title: CEO Date: October 24, 2024 2 Pharming Group reports third quarter 2024 financial results and provides business update • Third quarter 2024 total revenues increased by 12% to US$74.8 million, compared to the third quarter 2023, driven by continued strong RUCONEST® and Joenja® revenue growth • RUCONEST® third quarter revenu e increased by 6% to US$63.6 million, compared to the third quarter 2023 • Joenja® (leniolisib) third quarter reven ue increased b y 72% to US$11.2 million, compared to the third quarter 2023 • First nine months total revenu es increased by 25% to US$204.5 million, compared to the first nine months 2023 • On track for 2 024 total revenue guidance of US$280 million - US$295 million (14 - 20% growth) • Third quarter operating profit increased to US$4.1 million from US$1.9 million in the third quarter 2023 • Overall cash and marketable securities increased to US$173.3 million at the end of the third quarter 2024 from US$161.8 million at the end of the second quarter 2024 • Sijmen de Vries, our Executive Director/Chief Executive Officer, has informed the Board of Directors that he will not be available for reappointment at the next Annual General Meeting of Shareholders in May 2025 • Pharming to host a conference call today at 13:30 CEST (7:30 am EDT) Leiden, the Netherlands, October 24, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/NASDAQ: PHAR) presents its preliminary, unaudited financial report for the three months ended September&

View on Read The Filing